Stephen Jones STEPHEN JONES, US Oncology Research, Houston Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival adva
Stephen Jones
STEPHEN JONES, US Oncology Research, Houston
Long term data from an early breast cancer trial involving cyclophosphamide combined with docetaxel or doxorubicin have shown a survival advantage for the taxane. As Stephen Jones of US Oncology Research explained to Derek Thorne, this advantage was also seen in patients over 65.
LISTEN
[audio:https://www.audiomedica.com/podcasting/oncology/071213_stephen_jones.mp3]